RVMD Quote, Financials, Valuation and Earnings

Electromed has a net margin of -- compared to Revolution Medicines's net margin of 12.06%. Revolution Medicines's return on equity of -- beat Electromed's return on equity of 16.57%.

Revolution Medicines has a consensus price target of $72.25, signalling upside risk potential of 88.15%. On the other hand Electromed has an analysts' consensus of $33.50 which suggests that it could grow by 81.87%. Given that Revolution Medicines has higher upside potential than Electromed, analysts believe Revolution Medicines is more attractive than Electromed.

Revolution Medicines has a beta of 1.063, which suggesting that the stock is 6.289% more volatile than S&P 500. In comparison Electromed has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.696%.

Revolution Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Revolution Medicines pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Revolution Medicines quarterly revenues are --, which are smaller than Electromed quarterly revenues of $15.7M. Revolution Medicines's net income of -$213.4M is lower than Electromed's net income of $1.9M. Notably, Revolution Medicines's price-to-earnings ratio is -- while Electromed's PE ratio is 23.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revolution Medicines is -- versus 2.69x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of -- compared to Revolution Medicines's net margin of -35.24%. Revolution Medicines's return on equity of -- beat Myomo's return on equity of -38.11%.

Revolution Medicines has a consensus price target of $72.25, signalling upside risk potential of 88.15%. On the other hand Myomo has an analysts' consensus of $8.70 which suggests that it could grow by 346.15%. Given that Myomo has higher upside potential than Revolution Medicines, analysts believe Myomo is more attractive than Revolution Medicines.

Revolution Medicines has a beta of 1.063, which suggesting that the stock is 6.289% more volatile than S&P 500. In comparison Myomo has a beta of 1.389, suggesting its more volatile than the S&P 500 by 38.863%.

Revolution Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Revolution Medicines pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

Revolution Medicines quarterly revenues are --, which are smaller than Myomo quarterly revenues of $9.8M. Revolution Medicines's net income of -$213.4M is lower than Myomo's net income of -$3.5M. Notably, Revolution Medicines's price-to-earnings ratio is -- while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revolution Medicines is -- versus 1.97x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of -- compared to Revolution Medicines's net margin of -2201.34%. Revolution Medicines's return on equity of -- beat VolitionRX's return on equity of --.

Revolution Medicines has a consensus price target of $72.25, signalling upside risk potential of 88.15%. On the other hand VolitionRX has an analysts' consensus of $2.94 which suggests that it could grow by 320%. Given that VolitionRX has higher upside potential than Revolution Medicines, analysts believe VolitionRX is more attractive than Revolution Medicines.

Revolution Medicines has a beta of 1.063, which suggesting that the stock is 6.289% more volatile than S&P 500. In comparison VolitionRX has a beta of 1.198, suggesting its more volatile than the S&P 500 by 19.798%.

Revolution Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Revolution Medicines pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

Revolution Medicines quarterly revenues are --, which are smaller than VolitionRX quarterly revenues of $246.4K. Revolution Medicines's net income of -$213.4M is lower than VolitionRX's net income of -$5.4M. Notably, Revolution Medicines's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revolution Medicines is -- versus 48.25x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -- compared to Revolution Medicines's net margin of 0.18%. Revolution Medicines's return on equity of -- beat Xtant Medical Holdings's return on equity of -26.62%.

Revolution Medicines has a consensus price target of $72.25, signalling upside risk potential of 88.15%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 201.72%. Given that Xtant Medical Holdings has higher upside potential than Revolution Medicines, analysts believe Xtant Medical Holdings is more attractive than Revolution Medicines.

Revolution Medicines has a beta of 1.063, which suggesting that the stock is 6.289% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.139, suggesting its less volatile than the S&P 500 by 113.918%.

Revolution Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Revolution Medicines pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Revolution Medicines quarterly revenues are --, which are smaller than Xtant Medical Holdings quarterly revenues of $32.9M. Revolution Medicines's net income of -$213.4M is lower than Xtant Medical Holdings's net income of $58K. Notably, Revolution Medicines's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revolution Medicines is -- versus 0.65x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.